Form 4: Director Roush Acquires LMAT Dividend Rights

Lemaitre Vascular Director John A. Roush reported the acquisition of dividend equivalent rights tied to previously granted equity awards.

Summary

• John A. Roush, a Director of Lemaitre Vascular Inc. (LMAT), reported the acquisition of dividend equivalent rights (DERs) on March 26, 2026.
• The DERs accrued on various restricted stock unit (RSU) and performance share unit (PSU) awards granted on December 8, 2023, December 6, 2024, and December 10, 2025.
• Specifically, 0.3941 DERs accrued on an RSU award from 12/8/2023, 0.472 DERs on a PSU award from 12/8/2023, 0.6426 DERs on an RSU award from 12/6/2024, 0.7276 DERs on a PSU award from 12/6/2024, and 1.2077 DERs on an RSU award from 12/10/2025.
• Each dividend equivalent right is the economic equivalent of one share of Lemaitre Vascular's common stock and vests proportionately with its underlying award.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects the ongoing accrual of equity-linked compensation for a director, aligning their interests with shareholders, but does not represent a new, active investment.

Positives

• The accrual of dividend equivalent rights aligns the director's financial interests with those of common shareholders, as the value of these rights is tied to the company's stock performance.
• The transaction was executed under a Rule 10b5-1(c) plan, which suggests a pre-planned, non-discretionary transaction, reducing concerns about opportunistic insider trading.

Negatives

• The reported transactions represent passive accruals of rights rather than active, open-market purchases, meaning there is no new direct cash investment by the director into the company's stock.

Risks

• The value of the dividend equivalent rights is subject to the future performance and vesting conditions of the underlying restricted stock units and performance share units.
• The ultimate value realized from these rights is dependent on the market price of Lemaitre Vascular's common stock at the time of vesting and conversion.

Future Outlook

The dividend equivalent rights will vest proportionately with their underlying restricted stock unit and performance share unit awards, implying future conversion into common stock upon satisfaction of vesting conditions.

Industry Context

StockSavvy.ai notes that insider filings like Form 4 provide transparency into executive and director compensation and ownership, which is a standard practice across the medical device industry. The use of dividend equivalent rights tied to equity awards is a common mechanism to ensure that executives and directors benefit from dividends declared on shares they are yet to fully own, further aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Share Units (PSUs) with accompanying Dividend Equivalent Rights (DERs) is a standard component of executive and director compensation packages in the medical device industry.
• Companies such as Medtronic (MDT) and Boston Scientific (BSX) frequently utilize similar equity-based incentives to attract and retain talent, aligning management's long-term interests with shareholder returns.
• The accrual of DERs at a $0 price is typical for such rights, as they represent the economic equivalent of dividends on unvested shares, rather than a direct purchase.

Related Party Transactions

• The accrual of dividend equivalent rights to a director is a related party transaction, as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The accrual of equity-linked rights for a director reinforces alignment between management and shareholder interests, potentially encouraging long-term value creation.
• Employees: The compensation structure for directors can set a precedent or reflect the broader equity compensation philosophy within the company.

Next Steps

• The underlying Restricted Stock Unit and Performance Share Unit awards, along with the accrued dividend equivalent rights, will vest according to their respective schedules.
• Upon vesting, the dividend equivalent rights will convert into shares of Lemaitre Vascular common stock.

Key Dates

Recommendation

This Form 4 filing reports routine accruals of dividend equivalent rights as part of an existing equity compensation plan for a director. It does not indicate any new strategic developments, significant financial performance, or active investment decisions that would warrant a change in investment recommendation. It merely reflects the ongoing alignment of director interests with shareholders through standard compensation practices.

Keywords

Lemaitre Vascular, LMAT, Form 4, Insider Transaction, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Equity Compensation, Director Ownership, Rule 10b5-1